RecruitingPhase 3NCT07080931

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia

Sponsor

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Enrollment

294 participants

Start Date

Feb 24, 2025

Study Type

INTERVENTIONAL

Conditions

androgenetic alopecia

Summary

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 5% minoxidil foam and a drug called Placebo for 5% Minoxidil Foam for people with androgenetic alopecia. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG5% minoxidil foam

Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

DRUGPlacebo for 5% Minoxidil Foam

Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.